TM6SF2-rs58542926基因型在社区队列中对肝脏事件与心脏事件发生率的相反效应
基于英国生物银行前瞻性队列超过43万人的数据,采用Fine-Gray竞争风险分析发现,TM6SF2-rs58542926-TT基因型较CC基因型与肝脏相关事件发生率升高相关(校正sHR 3.16,95%CI 1.86-5.37),而与主要不良心血管事件发生率降低相关(校正sHR 0.76,95%CI 0.63-0.91)。在纤维化-4评分>2.67的个体中,肝脏相关事件绝对增加超过主要不良心血管事件绝对减少;该关联在男性中显著而在女性中不显著。
要点
- TM6SF2-rs58542926-TT较CC基因型肝脏相关事件风险升高(校正sHR 3.16,95%CI 1.86-5.37)。
- TM6SF2-rs58542926-TT较CC基因型主要不良心血管事件风险降低(校正sHR 0.76,95%CI 0.63-0.91)。
- 纤维化-4评分>2.67时肝脏相关事件绝对增加超过主要不良心血管事件绝对减少。
核心结论
- TM6SF2基因型对肝脏相关事件与主要不良心血管事件发生率具有相反效应,除纤维化-4评分最高者外主要不良心血管事件的绝对效应更大,效应在男性中最强。
- 这些发现基于个体化临床风险阐明了TM6SF2基因型的意义。
研究设计与样本
- 使用英国生物银行前瞻性队列,纳入具有遗传和住院诊断数据的个体,超过43万人符合纳入标准。
- 主要预测因素为TM6SF2-rs58542926基因型,主要结局为主要不良心血管事件和肝脏相关事件,采用Fine-Gray竞争风险分析报告亚分布风险比(sHR)和10年累积发生率。
主要发现
- TM6SF2-rs58542926-TT基因型(对比CC)与肝脏相关事件发生率升高相关(校正sHR 3.16,95%CI 1.86-5.37),与主要不良心血管事件发生率降低相关(校正sHR 0.76,95%CI 0.63-0.91)。
- 纤维化-4<1.3、1.3-2.67和>2.67的个体中,TM6SF2-rs58542926-TT对比CC的10年肝脏相关事件发生率分别为0.08% vs 0.06%(P>0.05)、0.81% vs 0.20%(P<0.0001)和10.5% vs 3.4%(P=0.00094)。
- 对应主要不良心血管事件值分别为3.8% vs 5.1%(P=0.032)、6.4% vs 8.2%(P=0.040)和17.1% vs 12.4%(P>0.05)。
- 除纤维化-4>2.67组外,rs58542926-TT(对比CC)基因型的主要不良心血管事件绝对减少超过肝脏相关事件绝对增加。
- TM6SF2基因型与肝脏相关事件/主要不良心血管事件的关联在男性中显著而在女性中不显著;TM6SF2-rs58542926-T等位基因还与磁共振成像肝脂肪变增加和校正T1时间延长相关,男性效应量大于女性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: TM6SF2 -rs58542926-T is associated with increased cirrhosis and modestly decreased coronary artery disease prevalence. However, relative effects of TM6SF2 genotype on major adverse cardiovascular events (MACE) vs liver-related events (LRE) are not known. METHODS: We used the UK Biobank, a prospective cohort with genetic and inpatient diagnosis data. The primary predictor was TM6SF2 -rs58542926 genotype, and the primary outcomes were MACE and LRE. Effects were reported as subhazard ratios (sHRs) and 10-year cumulative incidence by Fine-Gray competing risk analyses. RESULTS: More than 430,000 individuals met inclusion criteria. TM6SF2 -rs58542926-TT genotype (vs CC) was associated with higher incidence of LRE (adjusted sHR 3.16, 95% confidence interval 1.86-5.37) and lower incidence of MACE (adjusted sHR for TT vs CC genotype 0.76, 95% confidence interval 0.63-0.91). In individuals with fibrosis-4 (FIB4) < 1.3, 1.3-2.67, and > 2.67, 10-year LRE incidence in TM6SF2 -rs58542926-TT vs CC individuals was 0.08% vs 0.06% ( P > 0.05), 0.81% vs 0.20% ( P < 0.0001), and 10.5% vs 3.4% ( P = 0.00094), respectively. The corresponding values for MACE were 3.8% vs 5.1% ( P = 0.032), 6.4% vs 8.2% ( P = 0.040), and 17.1% vs 12.4% ( P > 0.05). The absolute decrease in MACE with rs58542926-TT (vs CC) genotype exceeded the absolute increase in LRE in all groups but FIB4 > 2.67. Associations of TM6SF2 genotype with LRE/MACE were significant in men but not women. TM6SF2 -rs58542926-T allele was also associated with increased hepatic steatosis and corrected T1 time by magnetic resonance imaging, with greater effect sizes in men than women. DISCUSSION: TM6SF2 genotype has opposite effects on LRE vs MACE incidence, and absolute effects on MACE were greater except in those with highest FIB4 scores. Effects were strongest in men. These findings clarify implications of TM6SF2 genotype based on personalized clinical risk.
引用
- Chen VL, Oliveri A, Raut C, et al. TM6SF2 -rs58542926 Genotype Has Opposing Effects on Incidence of Hepatic and Cardiac Events in a Community Cohort. Am J Gastroenterol. 2024. PMID: 39471479. doi:10.14309/ajg.0000000000003169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。